Cooling Tech Heats Up 16% Higher Before the Print

An under-the-radar industrial firm is heating up ahead of earnings, a fintech giant just posted strong results but still dropped on the open, and a design software leader is flexing pricing power as AI demand accelerates. Here's what traders are watching today.

Healthcare is being rewritten by AI—and one under-the-radar tech firm is already transforming how hospitals, insurers, and pharma giants operate.

While most companies are still testing ideas, this one is deploying real AI solutions across over 300 hospitals internationally.

From cloud-based IT services to real-time clinical data systems and predictive analytics, this company isn’t just talking about digital transformation—it’s building it.

Its new AI subsidiary is focused on solving massive pain points:

– Mental health access
– Hospital efficiency
– Data overload

After two key acquisitions, its platform now combines machine learning, automation, and scalable SaaS tools—all targeting one of the fastest-growing global market

And the numbers back it up:

✔ AI in healthcare is projected to grow 20x by 2034
✔ Digital health could hit $2.3 trillion in the same period

This firm has strong financials, real traction, and a product suite already in use.

The upside potential? Significant. But once larger players catch on, the edge may disappear.

[Click here to read the full report]

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Premarket Earnings:

Aftermarket Earnings:

Economic Reports:

How would it feel to double your money by this time next year?

From thousands of stocks, only 5 have emerged with the best chance to gain +100% or more in the months ahead.

You can see all five of these tickers — absolutely free.

Just download the newly released 5 Stocks Set to Double special report from Zacks.

While we can’t guarantee future performance, previous editions of this report have delivered gains of +175%, +498%, and even +673¹.

The newest picks could be just as profitable.

Download the report now, absolutely free

*Results may not represent all stock picks and may reflect partially closed positions. Investing involves risk, and past performance does not guarantee future results. This is not financial advice.

PayPal [PYPL] delivered a solid Q2 earnings beat this morning, raising full-year guidance on the back of strong Venmo momentum and continued payment volume growth. Despite the upbeat results, shares dipped 4% in premarket trading and are now trading flat, giving long-term investors a potential entry point.

Adjusted earnings per share came in at $1.40, ahead of the $1.30 estimate, while revenue reached $8.29 billion, up 5% year over year. Transaction margin dollars, a key profitability metric, climbed 7% to $3.84 billion, marking the sixth straight quarter of improvement. Total payment volume hit $443.6 billion, surpassing analyst expectations, with active user accounts ticking up to 438 million.

Venmo stood out as a highlight. Revenue from the peer-to-peer platform jumped more than 20% for the second consecutive quarter, while debit card usage soared 40%. The launch of co-branded debit cards and growing adoption in Germany for PayPal’s mobile wallet reflect a broader strategy to diversify revenue beyond traditional checkout services.

PayPal also unveiled its new cross-wallet platform, “PayPal World,” which aims to connect nearly two billion users across major ecosystems like Mercado Pago and UPI. Management is pushing into AI-driven commerce tools and stablecoin integration as part of a longer-term vision to remain competitive in an evolving payments landscape.

While a 42% drop in free cash flow raised some eyebrows, PayPal maintained its $6–7 billion full-year target and increased its share repurchase program.

With shares down over 9% YTD and trading at just 17.5x forward earnings, today’s weakness may offer upside for investors who believe in the turnaround story.

Chart Industries [GTLS] surged over 16% in premarket trading as investors look ahead to the company’s second-quarter earnings report, set for release tomorrow morning. Analysts are forecasting EPS of $2.62 and revenue of $1.12 billion, representing year-over-year growth of more than 20% and 7%, respectively.

Beneath the top-line numbers, the market will be watching closely for updates across Chart’s four major segments. Analysts expect Specialty Products and Heat Transfer Systems to post double-digit sales growth, while Repair, Service & Leasing could see a modest pullback.

Cryo Tank Solutions, one of the weaker segments last quarter, is also expected to decline slightly. But the bigger story is backlog: estimates point to a record $5.24 billion, up from $4.43 billion a year ago. That includes strong growth in Heat Transfer Systems and Specialty Products, both key drivers of margin expansion.

Investors are also eyeing commentary related to Chart’s planned merger with Flowserve, which would create a $19 billion enterprise with expanded exposure to LNG, hydrogen, and aftermarket services. UBS has maintained a $225 price target and Buy rating, citing merger synergies and resilient industrial demand. BTIG has echoed that view, with a $210 target.

With the stock still down nearly 10% for the year prior to this bounce and trading well below analyst targets, tomorrow’s report could be a turning point. A solid earnings beat paired with a confident integration outlook may trigger a re-rating and renewed momentum in the back half of 2025.

The escalating U.S.-China trade tensions are reshaping the AI landscape.

Companies like Nvidia are facing significant revenue hits with the U.S. imposing new export restrictions on advanced AI chips to China.

This shift opens doors for U.S.-based AI companies poised to fill the gap. I’ve identified 9 under-the-radar AI stocks with:

Access our FREE report, "Top 9 AI Stocks for This Month" to discover these opportunities before the broader market catches on.

Cadence Design Systems [CDNS] jumped over 8% in premarket trading Tuesday after delivering a strong second-quarter earnings beat and boosting its full-year outlook. The semiconductor design software firm reported adjusted EPS of $1.65 on revenue of $1.28 billion, up 29% and 20% from a year ago, respectively. Both metrics topped consensus estimates.

Management raised its full-year EPS guidance to $6.90 and revenue to $5.24 billion, slightly ahead of analysts’ expectations. CEO Anirudh Devgan pointed to strength in AI-driven design, autonomous systems, and next-gen science computing as key growth areas.

He emphasized “exceptional Q2 bookings,” reinforcing Cadence’s growing relevance in the AI buildout across sectors.

The company continues to benefit from structural demand for chip design automation and verification tools. Cadence’s CAC payback period came in under seven months, reflecting high efficiency in new customer acquisition. Despite a year-over-year dip in operating margins, free cash flow margins remain strong at 26.1%, and customer churn remains low.

CDNS had already broken out earlier this month above $326, and Monday’s earnings strength puts it on track to test new highs. The company’s ability to convert AI momentum into real bookings and margin stability has helped it stand out amid volatility in the broader software sector.

While the valuation remains elevated at a forward P/E above 80, Cadence’s long-term narrative continues to improve.

For investors looking to ride the semiconductor infrastructure wave, the stock is increasingly viewed as a core holding rather than a high-beta trade.

GeneDx is a genetic diagnostics company focused on delivering personalized testing across rare diseases, oncology, and exome sequencing. The company has become a key player in precision medicine and saw a dramatic revenue expansion over the past year.

Shares are soaring more than 26% in premarket trading after a massive earnings beat. Q2 EPS came in at $0.50 versus the expected $0.12, and revenue hit $102.7 million, easily beating the $85.4 million forecast. Full-year guidance was raised to $400–$415 million, well ahead of prior analyst expectations.

Apellis develops therapies that target the complement system, a part of the immune response involved in several rare diseases. Its key product, EMPAVELI, was already approved in other indications, but this week’s news extends its commercial runway.

The FDA approved EMPAVELI for C3 glomerulopathy (C3G) and IC-MPGN, making it the first approved treatment for these rare kidney conditions. Shares are up around 15% premarket as investors digest the broader label and sizable addressable market.

Flowserve is an industrial machinery company that builds pumps, valves, and mechanical seals used across energy, water, and chemical industries. It’s been working to expand margins and recurring aftermarket revenue.

Shares are up nearly 6% premarket after strong Q2 results and an upward revision to full-year earnings guidance. Bookings hit $1.1 billion, and operating margin expansion reflects success in their 3D Growth Strategy. Despite breaking off its merger with Chart Industries, Flowserve secured a $266 million termination fee that adds flexibility.

Market volatility, policy shifts, and economic tension are leaving many investors overwhelmed.

But buried under the chaos are clear signals of opportunity — if you know where to look.

That’s why we created a free, exclusive guide highlighting 7 stocks positioned for growth as 2025 progresses.

This report includes:

Even in uncertain times, preparation separates winners from watchers.

Download your copy today and get one step closer to smarter, faster trades.

[Claim your free report now]

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.